Filing Details
- Accession Number:
- 0001209191-20-042033
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-07-09 18:51:37
- Reporting Period:
- 2020-07-07
- Accepted Time:
- 2020-07-09 18:51:37
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1178879 | Amicus Therapeutics Inc. | FOLD | Pharmaceutical Preparations (2834) | 200422823 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1601896 | Jay Barth | C/O Amicus Therapeutics, Inc. 1 Cedar Brook Drive Cranbury NJ 08512 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-07-07 | 51,531 | $8.61 | 214,735 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-07-07 | 64,601 | $9.03 | 279,336 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-07-07 | 12,804 | $10.04 | 292,140 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-07-07 | 50,052 | $12.28 | 342,192 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-07-07 | 178,988 | $15.90 | 163,204 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-07-08 | 16,910 | $8.61 | 180,114 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-07-08 | 16,549 | $9.03 | 196,663 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-07-08 | 8,599 | $10.04 | 205,262 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-07-08 | 22,052 | $12.28 | 227,314 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-07-08 | 64,110 | $15.92 | 163,204 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (right to buy) | Disposition | 2020-07-07 | 51,531 | $0.00 | 51,531 | $8.61 |
| Common Stock | Stock Options (right to buy) | Disposition | 2020-07-07 | 64,601 | $0.00 | 64,601 | $9.03 |
| Common Stock | Stock Options (right to buy) | Disposition | 2020-07-07 | 12,804 | $0.00 | 12,804 | $10.04 |
| Common Stock | Stock Options (right to buy) | Disposition | 2020-07-07 | 50,052 | $0.00 | 50,052 | $12.28 |
| Common Stock | Stock Options (right to buy) | Disposition | 2020-07-08 | 16,910 | $0.00 | 16,910 | $8.61 |
| Common Stock | Stock Options (right to buy) | Disposition | 2020-07-08 | 16,549 | $0.00 | 16,549 | $9.03 |
| Common Stock | Stock Options (right to buy) | Disposition | 2020-07-08 | 8,599 | $0.00 | 8,599 | $10.04 |
| Common Stock | Stock Options (right to buy) | Disposition | 2020-07-08 | 22,052 | $0.00 | 22,052 | $12.28 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 28,469 | 2025-01-02 | No | 4 | M | Direct | |
| 25,399 | 2026-01-04 | No | 4 | M | Direct | |
| 69,840 | 2029-01-02 | No | 4 | M | Direct | |
| 39,948 | 2025-06-01 | No | 4 | M | Direct | |
| 11,559 | 2025-01-02 | No | 4 | M | Direct | |
| 8,850 | 2026-01-04 | No | 4 | M | Direct | |
| 61,241 | 2029-01-02 | No | 4 | M | Direct | |
| 17,896 | 2025-06-01 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 20 | Indirect | By Daughter |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.90 to $15.91. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.90 to $16.12 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- All of the options were fully vested and exercisable as of the transaction date.
- As of July 7, 2020, 30,987 options were fully vested and exercisable and 51,657 remained unvested from this grant.
- As of July 8, 2020, 18,183 options were fully vested and exercisable and 51,657 remained unvested from this grant.
Billionaire Hedge Funds
